anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SIGNIFICANCE: Results of this study provide preliminary data on parent strategies for improving compliance with eyeglass treatment in young children, an age group for which previous data are limited. Parent responses provide important insights to support parents of young children who wear eyeglasses and provide preliminary data to guide additional research.
PURPOSE: The goal of this exploratory study was to learn more about parents' strategies to improve compliance with eyeglass treatment of young children.
METHODS: An online survey of parents of 1-year-old to less than 5-year-old children who wear eyeglasses was conducted. Parents indicated whether they used various strategies to encourage wear and were asked to provide advice for parents of young children recently prescribed eyeglasses. Use of various strategies by age was determined. Open-ended responses regarding advice for other parents were analyzed using qualitative content analysis.
RESULTS: The final sample included 104 parents who were predominantly White (81%), non-Hispanic (76%), and college graduates (68%). During the 2 weeks prior to survey completion, 74% of parents reported their child wore their eyeglasses ≥8 hours/day. Use of strategies for improving eyeglass wear varied by child age. The most frequent recommendations that parents provided for other parents were to be consistent in encouraging wear, use social modeling, provide positive reinforcement when the eyeglasses are worn, and ensure that the eyeglasses fit well and were comfortable.
CONCLUSIONS: Parents provided many useful insights into their experiences. However, results may not be broadly generalizable, because of the limited diversity and high rate of compliance in the study sample. Further research with more diverse populations and research on effectiveness of various strategies to increase compliance in this age group are recommended to support eyeglass treatment compliance in young children.
PURPOSE: An increase method of fused protein into living cells or organs by adding levosulpiride to fused protein in which protein transport domains and therapeutic protein are covalently bonded is provided to increase therapeutic effects of protein medicines for various diseases. CONSTITUTION: An increase method of fused protein into living cells or organs is processed by adding levosulpiride to fused protein in which protein transport domains and therapeutic protein are covalently bonded. The levosulpiride is primarily processed in the living cells or organs than the fused protein. A protein transport domain is Tat, PEP-1, oligolysine, oligo arginine or oligo(lysine and arginine). The therapeutic protein is rpS3. A composition for preventing and treating inflammatory diseases comprises fused proteins in which is covalently bonded with the protein transport domain and levosulpiride. The inflammation therapeutic protein is rpS3. A composition for preventing and improving skin external application comprises fused proteins in which is covalently bonded with the protein transport domain and levosulpiride.
BACKGROUND: Hypoperfusion and the resulting hypoxia in solid tumours are critical causes of treatment resistance. Ultrasound-stimulated microbubbles (USMB) enhance tumour perfusion in a mechanism named the "sononeoperfusion" effect, which may relieve tumour hypoperfusion and hypoxia. The aim of this study was to determine the optimal mechanical index (MI) and therapeutic ultrasound exposure time for the sononeoperfusion effect and preliminarily explore the mechanism of sononeoperfusion and its effect on tumours.
METHODS: A total of 155 mice bearing MC38 tumours were included in this study. A modified diagnostic ultrasound and microbubbles (Zhifuxian) was used for USMB treatment. Tumour perfusion was evaluated by contrast-enhanced ultrasound (CEUS) and Hoechst 33342. The therapeutic pulse was operated with MIs of 0.1 to 0.5. The ultrasound exposure time was set from 150 s to 600 s. Endothelial nitric oxide synthase (eNOS) inhibition and NO, ATP, and phospho-eNOS (p-eNOS) detection were performed to explore the mechanisms of sononeoperfusion. Hypoxia-inducible factor-1α (HIF-1α) and tumour oxygen partial pressure (pO2) represent hypoxic tumour conditions.
RESULTS: Tumour perfusion was increased after USMB treatment at MIs of 0.1-0.4 and ultrasound exposure times of 150 s to 600 s, with optimal augmentation achieved at an MI of 0.3 and ultrasound exposure time of 450 s. The mean fluorescence intensity of Hoechst 33342 after USMB treatment was stronger than that of the control group. Biochemical assays showed a significant increase in ATP, p-eNOS and NO after USMB treatment. PO2 in tumour tissue increased significantly after USMB treatment and was maintained for more than 20 min.
CONCLUSIONS: The best sononeoperfusion effect was obtained with an MI of 0.3 and an ultrasound exposure time of 450 s. The effect is most likely related to NO and ATP increases. The sononeoperfusion effect might be a novel way to ameliorate tumour hypoperfusion and hypoxia.
An ejection tray is provided for use in combination with a medication container including a medication-containing cell. The tray includes a frame configured to receive at least a portion of the medication container. An actuator is movably associated with the frame to eject the medication from the cell. A switch is associated with the frame and configured to change from a first state to a second state upon the actuator being moved to eject the medication from the cell. A host processor is associated with the frame and is electrically coupled or selectively coupled to the switch. The host processor is programmed to detect a change in the state of the switch.
The invention discloses the effect target of a medicine for treating tumors and indications thereof. The medicine is extracted from tea leaves of which the safety is confirmed by eating for thousands of years. The medicine has a definite chemical structure, namely epigallocatechin gallate with the English name of (-)-Epigallocatechin gallate, EGCG for short. The research of the invention shows that the effect target of the medicine and a preparation thereof in cells is the NOTCH protein of people or animals. The medicine and the preparation thereof have the effect mechanism of suppressing the abnormal activation of an NOTCH signal. The medicine adapts to the treatment of tumors with abnormal NOTCH signals. Because the abnormity of the NOTCH signals nearly occurs in all tumor cells and the medicine and the preparation thereof also have higher safe dose, the medicine and the preparation thereof have extensive and definite market application prospect.
This invention relates to a delivery device of the bleeding hole type, where a primary drive fluid, e.g. silicon oil, is used to expel a secondary fluid, e.g. a drug, contained in a reservoir. To provide a desired drug flow rate, the primary fluid is forced from a first reservoir through a flow restrictor into a second reservoir displacing a portion of the drug reservoir, thereby expelling the drug from its reservoir. The idea is to provide a drive fluid outlet, i.e. a flow restrictor inlet, which protrudes into the first reservoir. By this arrangement the amount of particles and air-bubbles entering the narrow flow restrictor will be reduced. The reduction is achieved because particles and air-bubbles will normally concentrate in the top or bottom of the reservoir, whereas the protrusion will primarily connect to the centre of the first reservoir.
Borderline elevations of one or more liver tests may occur in upto 15% of patients taking NSAIDs, including IBU tablets. These laboratoryabnormalities may progress, may remain unchanged, or maybe transient with continuing therapy. Notable elevations of ALT orAST (approximately three or more times the upper limit of normal)have been reported in approximately 1% of patients in clinical trialswith NSAIDs. In addition, rare cases of severe hepatic reactions,including jaundice, fulminant hepatitis, liver necrosis, and hepaticfailure, some of them with fatal outcomes have been reported. Apatient with symptoms and/or signs suggesting liver dysfunction, orwith abnormal liver test values, should be evaluated for evidence ofthe development of a more severe hepatic reaction while on therapywith IBU tablets. If clinical signs and symptoms consistent with liverdisease develop, or if systemic manifestations occur (e.g.,eosinophilia, rash, etc.), IBU tablets should be discontinued.
An inhalation system including a fluid transfer member, a valve member, a cartridge assembly, and a mouthpiece, and a method of use thereof are provided. The valve member connects to an open end of the fluid transfer member. The cartridge assembly, positioned within the valve member, includes a substance holder and an absorbent member accommodated within a cartridge for containing and absorbing an inhaling substance. When the valve member connects to a vaporizer, the vaporizer heats the absorbent member to vaporize and release an inhaling fluid into the fluid transfer member. When the valve member connects to the mouthpiece, the valve member receives and transfers the inhaling fluid vapor from the fluid transfer member to a user's mouth via the mouthpiece. The locking mouthpiece assembly allows authentication of the user prior to releasing the inhaling fluid to the user's mouth.
PROBLEM TO BE SOLVED: To obtain the subject liquid medicine stable for a long period without reducing its high antiinflammatory action and useful as an eye drop by adding a specific glycyrrhizic acid compound to a liquid medicine containing a nonionic ester surfactant. SOLUTION: The alkyl ester of a glycyrrhizic acid of formula I or II (R1 -R3 are each H, an alkali metal, NH4 , an alkyl, wherein at least one of R1 -R3 is the alkyl) or its pharmacologically acceptable salt is added to an aqueous solution containing a nonionic ester surfactant. The glycyrrhizic acid alkyl ester is e.g. glycyrrhizic acid dipotassium monomethyl ester obtained by esterifying a carboxyl group on the triterpene of β-glycyrrhizic acid dipotassium salt. The glycyrrhizic acid alkyl ester is added in an amount of approximately 0.01-5wt.% in the case of an eye drop. The nonionic ester surfactant is e.g. water-soluble polyoxyethylene hydrogenated castor oil.
After full completion of the Non-Invasive (NI) studies, and a defined algorithm to compute SpO2 by TDw1 is achieved, the study is repeated as described for the NI (Rapid-Sitting) protocol, but arterial blood oxygen saturation (SaO2) will be determined during 5 stable ambient oxygen plateaus (the Invasive (Fast-Sitting) study). These results are used as benchmark to define the final accuracy of TDw1 for SpO2 reproduction. In this part of the study, according to the minimal requirements of the regulatory agencies, 12 volunteers that successfully completed the study will be included.
Patients receive decitabine and cedazuridine PO daily on days 1-5 and venetoclax PO daily on days 1-28 of the first cycle and on days 1-21 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Abeta) protein or peptide. Anti-Abeta antibodies are selected and sequenced. In certain embodiments, synthetic Abeta binding peptides are designed and prepared, using portions of the anti-Abeta antibody sequences. The antibodies and peptides are of use for treatment of AD or for treatment of individuals at risk of developing AD. Compositions comprising anti-Abeta antibodies or Abeta binding peptides are also disclosed.
Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days.
Risk Summary

There are no available data on POTELIGEO use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In an animal reproduction study, administration of mogamulizumab-kpkc to pregnant cynomolgus monkeys from the start of organogenesis through delivery did not show a potential for adverse developmental outcomes at maternal systemic exposures 27 times the exposure in patients at the recommended dose, based on AUC (see Data). In general, IgG molecules are known to cross the placental barrier and in the monkey reproduction study mogamulizumab-kpkc was detected in fetal plasma. Therefore, POTELIGEO has the potential to be transmitted from the mother to the developing fetus. POTELIGEO is not recommended during pregnancy or in women of childbearing potential not using contraception.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

Data

Animal Data

The effects of mogamulizumab-kpkc on embryo-fetal development were evaluated in 12 pregnant cynomolgus monkeys that received mogamulizumab-kpkc once weekly by intravenous administration from the start of organogenesis through delivery at an exposure level 27 times higher than the clinical dose. Mogamulizumab-kpkc administration did not show a potential for embryo-fetal lethality, teratogenicity, or fetal growth retardation and did not result in spontaneous abortion or increased fetal death. In surviving fetuses (10 of 12 compared with 11 of 12 in the control group) of cynomolgus monkeys treated with mogamulizumab-kpkc, a decrease in CCR4-expressing lymphocytes due to the pharmacological activity of mogamulizumab-kpkc was noted; there were no apparent mogamulizumab-kpkc -related external, visceral, or skeletal abnormalities.
BACKGROUND: This study aimed to evaluate the application of metagenomic next-generation sequencing (mNGS) technology to identify pathogens in periprosthetic joint infection (PJI).
METHODS: A retrospective analysis was conducted on 65 patients suspected of having PJI between April 2020 and July 2023. The patients were categorized into PJI (46 patients) and non-PJI (19 patients) groups based on the 2018 International Consensus Meeting criteria. Clinical data were collected, and both conventional bacterial culture and mNGS were performed. The diagnostic performance of the two methods was compared and analyzed.
RESULTS: mNGS exhibited a sensitivity of 89.13%, a specificity of 94.74%, a positive predictive value of 97.62%, a negative predictive value of 78.26%, and an overall diagnostic accuracy of 90.77%. Compared to microbial culture, mNGS demonstrated superior diagnostic sensitivity while maintaining similar specificity. A total of 48 pathogens were successfully identified using mNGS, with Coagulase-negative staphylococci, Streptococci, Staphylococcus aureus, and Cutibacterium acnes being the most common infectious agents. Notably, mNGS was used to identify 17 potential pathogens in 14 culture-negative PJI samples, highlighting its ability to detect rare infectious agents, including Cutibacterium acnes (n = 5), Granulicatella adiacens (n = 1), Mycobacterium tuberculosis complex (n = 1), and Coxiella burnetii (n = 1), among others, which are not detectable by routine culture methods. However, mNGS failed to detect the pathogen in 4 culture-positive PJI patients, indicating its limitations. Among the 46 PJI patients, 27 had positive culture and mNGS results. The results of mNGS were concordant with those of culture at the genus level in 6 patients with PJI and at the species level in 18 patients. Furthermore, the present study revealed a significantly greater proportion of Staphylococcus aureus in the sinus tract group (45.45%) than in the non-sinus tract group (14.29%), indicating the association of this pathogen with sinus formation in PJI (P = 0.03). Additionally, there was no significant difference in the occurrence of polymicrobial infections between the sinus tract group (27.27%) and the non-sinus tract group (33.33%) (P = 0.37).
CONCLUSIONS: Metagenomic next-generation sequencing can serve as a valuable screening tool in addition to traditional culture methods to improve diagnostic accuracy through optimized culture strategies.
This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to drugs, a combined preparation, a pharmaceutical composition and a method for prophylaxis or treatment of inflammatory states or analgesia. Drug for treatment or prophylaxis of damage of gastroenteric tract caused by nonsteroid anti-inflammatory drugs is ranitidine bismuth-citrate or a pharmaceutical composition containing its. Combined preparation for treatment or prophylaxis of inflammatory states or for analgesia in human or animals has an effective amount of nonsteroid anti-inflammatory drug and an effective amount of the claimed drug. It is adopted for providing the simultaneous, separated or successive administration of indicated drugs. A pharmaceutical composition is made in the form for oral use and has nonsteroid anti-inflammatory drug, claimed drug and pharmaceutically acceptable carriers or filling agents. Claimed drug in the composition is taken at effective amount for prophylaxis of gastroenteric tract damage. Method of prophylaxis or treatment of inflammatory states or analgesia in human and animals involves administration of nonsteroid anti-inflammatory drug taken at effective amount and the claimed drug at effective amount is administrated before, after or simultaneously with nonsteroid anti-inflammatory drug. EFFECT: significant decreased degree of damage of gastroenteric tract mucosa. 16 cl, 1 tbl, 3 ex
The study will be conducted in accordance with legal and regulatory requirements with scientific purpose, value and rigor following generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP), Good Epidemiological Practice (GEP), Good Practices for Outcomes Research, International Ethical Guidelines for Epidemiological Research, European Medicines Agency (EMA) European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology, and FDA Guidance for Industry. Data sources will be validated and will consist of the hospital medical records and monitoring will be organized on a regular basis. Data sources will be validated. The source data will consist of medical records, physician questionnaires, and patient questionnaires. Data for the study will be entered into an electronic data capture system. Questionnaires will be completed on electronic tablets. The study is a one year enrollment period with a two year follow-up period. The study plans to enroll patients throughout Canada and Europe.
Use of at least one organo-silane compound (I) for the manufacture of a pharmaceutical preparation targeted to constrain the organization of protein fibers and glycoproteins of the extra-cellular matrix of injured conjunctive tissues. Use of at least one organo-silane compound (I) of formula: (R x-Si(OH) 4 -x) for the manufacture of preparation (especially pharmaceutical preparation), containing supra-physiological doses of (I), targeted to constrain the organization of protein fibers and glycoproteins of the extra-cellular matrix of injured conjunctive tissues; where (I) is stabilized by the formation of weak or strong bonds with an organic carrier (alcohol, phenol, acid, amine and/or amino acid). R : 1-4C alkyl, 2-5C alkenyl or aryl; and x : 1-3. ACTIVITY : Ophthalmological; Dermatological; Vulnerary. The effect of monomethylsilanetriol salicylate to treat wrinkles and cutaneous depression was tested in humans. The administration of monomethylsilanetriol salicylate provided amelioration of relief from the conditions in 40% of the patients after 3 months of treatment. MECHANISM OF ACTION : Collagenase inhibitor; Elastase inhibitor; Glucuronidase inhibitor.
Chronic use of opiates has long been associated with multiple side effects, many of which are due to lower levels of androgens in this patient population. Previous studies have shown that long-term opiate use may lead to narcotic induced hypogonadism, resulting in significantly decreased testosterone levels in men. One area of chronic opiate use that has not been looked at extensively is the correlation between narcotic-induced hypogonadism and associated side effects such as osteoporosis and sexual dysfunction in male patients receiving methadone maintenance therapy. Marked testosterone deficiency is a well-established rick factor for both osteoporosis and altered sexual function, and recent information demonstrated that altered estrogen levels may play a role in these side effects as well. Thre present pilot study investigates the role of sex steroids in male patients maintained on methadone therapy and their association with bone densitometry and sexual dysfunction. Free testosterone, estradiol, lutenizing hormone, sex hormone binding globulin, Vitamin D levels and albumin will be measured in thirty community-dwelling outpatient men participating in a methadone maintenance program as well as thirty age-matched controls from a general medicine clinic. Osteodensitometry will be performed with the DEXA technique at the lumbar spine. Participants will also complete the Brief Male Sexual Function Inventory as well as be assessed for smoking/alcohol use, calcium intake, physical activity, length of time receiving opiates as well as concurrent medications. It is hypothesized that patients receiving methadone maintenance therapy will have lower bone mass densities, free testosterone, estradiol, and sexual dysfunction scores than the age-matched controls.